Maarten A. Ligtenberg

Author

Also Known As

M. A. Ligtenberg, M. Ligtenberg, Maarten A Ligtenberg, Maarten A. Ligtenberg, Maarten Alexander Ligtenberg, Maarten Ligtenberg

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Oncode Institute Karolinska Institutet The Netherlands Cancer Institute Fundación Ciencia and Vida Utrecht University

About

Maarten A. Ligtenberg is an author at Oncode Institute specializing in immunology, medicine, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	806
2	Immunology	7	7	806
3	Cell Biology	4	4	86
4	Pharmacology	2	2	230
5	Autoimmunity	1	1	15

Maarten A. Ligtenberg

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Chikungunya Virus Nonstructural Protein 2 Inhibits Type I/II Interferon-Stimulated JAK-STAT Signaling Jelke J. Fros, Wen Jun Liu, Natalie A. Prow, Journal of Virology Viral ReplicationMolecular VirologyPathogenesisViral PathogenesisImmunology	2010	253
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold David W. Vredevoogd, Thomas Kuilman, Maarten A. Ligtenberg, Cell Immunotherapy ImpactCancer ImmunosurveillanceImmunologyImmunoeditingImmune Checkpoint Inhibitor	2019	252
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors Julia Boshuizen, Louise A. Koopman, Oscar Krijgsman, Nature Medicine Melanoma HeterogeneityAxl Antibody-drug ConjugateDrug TargetingMedicineMelanoma	2018	215
Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity Maarten A. Ligtenberg, Dimitrios Mougiakakos, Madhura Mukhopadhyay, The Journal of Immunology	2015	209
Reversal of pre-existing NGFR-driven tumor and immune therapy resistance Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Nature Communications	2020	115
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody–Drug Conjugate and Immune Checkpoint Blockade Julia Boshuizen, Nora Pencheva, Oscar Krijgsman, Cancer Research	2021	63
DAI (DLM-1/ZBP1) as a Genetic Adjuvant for DNA Vaccines That Promotes Effective Antitumor CTL Immunity Álvaro Lladser, Dimitrios Mougiakakos, Helena Tufvesson, Molecular Therapy	2010	58
Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma Maarten A. Ligtenberg, Yago Pico de Coaña, Taisia Shmushkovich, Molecular Therapy	2018	50
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling Georgi Apriamashvili, David W. Vredevoogd, Oscar Krijgsman, Nature Communications	2022	50
Abstract 4557: Tumor and CD8 T cells metabolism and consumption in the tumor microenvironment Lauranne Poncelet, Pierre Lévy, Rima Ait-Belkacem, Tumor Biology Molecular Image OverlayImmunologyBiological MicroenvironmentsImmunoeditingImmunotherapy	2019	41

Page 1